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consulting with low back pain. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 rates of were identified and an assessment of these indicated that two methods: within-the-table and at-themargins approaches were used for the analysis. With the exception of one study, all others did not consider interactions in costs and outcomes or give a detailed explanation of why a particular approach was adopted. The authors recommend that additional guidance is needed and further research is required to evaluate the impact of alternative methods on policy recommendations and establish good practice methods for the economic analysis of factorial trials.
Key words: cost-benefit analysis, cost-effectiveness, cost-utility analysis, economic evaluation, factorial design, factorial trial. . There are several factorial designs, with the most common being the 2x2 which assesses two interventions with each one of them having two levels. For example, in a 2x2 factorial trial of self-management options for hand osteoarthritis, patients can be randomised to either of the following interventions: usual care, joint protection, hand exercises or a combined intervention (joint protection plus hand exercises). This allows for more information to be obtained in a single trial at a reduced overall cost [5] . In addition, factorial trials allow for the investigation of interactions between the treatments under scrutiny [6] [7] , and in the absence of interactions, they provide greater power than traditional multiple-arm trials of similar sample size evaluating the same interventions [8] .
As a consequence, there is now a growing interest in employing these designs in trial-based economic evaluations [9] . However, unlike in the analysis of clinical outcomes, where the methods of analysis are well established, methods for the economic analysis of factorial trials remain unclear [10, 11] .
Recent research suggested that the appropriate analysis of factorial designs in economic evaluations is important, not only because interactions are more likely to occur in economic data but also because economic evaluations focus on the estimation of incremental cost-effectiveness ratios (ICERs) as opposed to hypothesis testing which is the main focus of clinical studies [10] . There is therefore a greater potential for bias which can affect the validity of results if the analysis is not carried out appropriately. In addition, this type of trial leads to a reduction in sample size if interactions are accounted for. This is problematic because most two arm trials are known to be underpowered for the economic analysis and as a consequence, the factorial trial could potentially lead to further uncertainty in economic outcomes [11] . Even though these challenges have been identified, there is still uncertainty about how to overcome them.
The objective of this study is to systematically review economic evaluations conducted alongside factorial trials with the aim of exploring the empirical methods involved and to offer recommendations that could potentially assist in the development of good practice guidelines in this context. To the best of our knowledge, no other study has conducted a systematic review of economic evaluations alongside factorial trials.
METHODS
A systematic review of economic evaluations alongside factorial trials was conducted following the guidelines outlined by the UK Centre for Review and Dissemination (CRD) [12] . In the absence of Medical Subject Heading (MeSH) for factorial trials and economic evaluations, search terms, including truncation where appropriate, included the terms "cost-benefit analysis", "cost-effectiveness analysis", "cost-utility analysis", "economic evaluation", "factorial design" and "factorial trial". The Table 1 .
To be included in the review, studies had to be full economic evaluations conducted alongside a factorial trial. Studies were excluded if they were partial or non-economic evaluation studies, cohort studies, case-control studies, systematic reviews, study protocols or commentaries. Non-English studies and grey literature were also excluded.
Literature search was carried out between July and August 2013 in two stages. First, titles and abstracts were screened to identify potentially relevant papers. The second stage involved screening were extracted concerning the perspective of the study and type of economic evaluation, cost and outcomes considered and method of analysis of factorial trials.
RESULTS
The electronic database search identified 135 potentially relevant papers of which 18 were duplicates.
Out of the 117 remaining papers, 92 were excluded after the screening of titles. A thorough assessment of the 25 papers identified to be potentially relevant led to the exclusion of a further 13
papers from the list, limiting the number of papers to 12. The 13 papers were excluded for the following reasons; 7 of them were study protocols, 3 were systematic reviews and 3 were not full economic evaluations. The reference lists of the 12 relevant papers were also screened and this led to the identification of 4 additional papers. A total of 16 papers were therefore included in the review. Figure 1 shows a flow chart of the papers identified, retrieved and retained or excluded at each stage of the review process.
Summary of selected studies
As shown in [19] . Three studies considered both a health service and societal perspective [16, 22, 25] and one considered all three [18] . In all the studies, the reason for adopting a particular perspective was given and this was appropriately followed for collecting the right cost data within the boundaries of the perspective adopted.
Two types of economic evaluations were mainly undertaken across the sixteen studies. These are costeffectiveness analysis (CEA) and cost-utility analysis (CUA) ( Table 2 ). CEA was undertaken in six studies, [13, 17, 19, 23, 26 ,27] whereas CUA was undertaken in nine studies, [14] [15] [16] [20] [21] [22] 24, 25, 28] with one study undertaking both cost-consequence and cost-utility analysis [18] . All studies gave a justification of why they employed each economic evaluation technique and it was found to be appropriate to the research objectives. The sample size of most studies (approximately 63%) was less than 800 participants. Only two studies recruited more than 3000 participants. 
Costs and outcomes
Six studies had their primary outcome of interest reported in cost per unit effect [13, 17, 19, 23, 26, 27] whereas ten studies reported their primary outcomes in cost per Quality Adjusted Life Year (QALY)
gained [14] [15] [16] 18, [20] [21] [22] 25, 28] or cost per Disability Adjusted Life Year (DALY) averted [24] . In terms of costing, all the studies adopted the ingredient approach (where estimates of total resource use are multiplied by their respective unit prices) to estimate the cost of the interventions. In all studies where the trials were conducted over a time horizon of one year, cost and QALYs were not discounted whereas in studies with larger time horizon costs and QALYs were discounted. . The at-the-margins approach implicitly assumes that the interventions under investigation are independent and there is no interaction between treatments. The trial is therefore analysed as though it were overlapping arms of an RCT comparing the effects of treatments separately [29] . One study considered both methods and stated that the reason for employing both methods was to provide the most relevant information for policy makers (within-thetable approach) and to carry out the analysis in line with the convention for a factorial design (at-themargins approach) [18] . A summary of the characteristics of both approaches are presented in table 3.
Analytical approaches to the economic analysis of factorial trials
It should be noted that apart from the choice of approach in the clinical study and the objective of the economic analysis, other factors such as sample size, disease area or comparator did not seem to have an influence on the choice of approach.
A thorough assessment of the studies reviewed indicated that, none of the studies tested interactions between treatments in terms of costs and outcomes nor gave a detailed explanation on how they were going to account for the factorial nature of the trial. The only instance where reference was made to interaction in cost was the study by The UK BEAM trial team [14] , where they mentioned a comparison of four distinct treatments although cost showed no interaction between treatments. In all other instances where studies mentioned an interaction was to reiterate whether any statistically significant interaction was evident in clinical outcomes, which then informed the decision about which method of analysis to adopt rather than testing for interactions in the economic outcomes.
DISCUSSION
The literature search indicated that two methods (within-the-table and at-the-margins approach) are commonly used in the economic analysis of factorial trials. The choice of method was found to be mainly influenced by the method adopted in the clinical study. It is therefore apparent that for some of the studies, even though the clinical trial detected interactions, if the objective was to calculate the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [14] .
None of the studies explored interactions between economic outcomes or stated the reasons why such interactions were not expected to occur. This is problematic as economic outcomes are different from the clinical ones, and thus special considerations should be given to their analysis. This may be due to a lack of clear guidance on how economic evaluations alongside factorial trials should be conducted and their methodological challenges.
One such challenge may relate to the sample size of the trial. In all studies, sample sizes used were calculated with the purpose of detecting the clinical effects of the interventions under scrutiny. The problem that arises here is that some trials may be inadequately powered to detect plausible clinical interactions [7, 30] , and thus the absence of proof of evidence for interactions is equated to proof of absence of evidence for interactions in the clinical outcomes [30] . Given that interactions are more likely to occur in economic outcomes rather than the clinical [10] this assumption is likely to be invalid. Even when interactions in economic outcomes are identified, conducting the appropriate analysis within-the-table may result in further loss of power and greater uncertainty to the economic results.
It is also worth stating that, unlike clinical outcomes that are generally normally distributed, economic outcomes generally follow a skewed distribution and are associated with a higher variance, which impact on the way they should be analysed [31, 32] . Therefore, even if the trial is adequately powered to detect the main difference in clinical outcome, it will be typically underpowered for the analysis of economic outcomes. But as can be seen from the sample sizes employed in the various trials, the issue of sample size in relation to the detection of interactions (in economic outcomes) and the use of appropriate sample size in relation to the distribution of the economic outcomes for their effective analysis were not appropriately taken into consideration by almost all the studies.
Only one study [18] employed both the at-the-margins and within-the-table approaches, and even though this study, like the rest, did not give an explicit explanation of how the factorial nature of the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 [33] [34] [35] [36] [37] .
To the best of our knowledge, this is the first study to review economic evaluations conducted alongside factorial trials and therefore provides a description of the current state of play in the economic analysis of factorial trials. A possible limitation is the broad nature of the research question.
This study was not limited to a particular disease area and it is quite possible that some studies might have been missed out. However, we made every effort to identify all relevant studies by developing the search strategy with advice from an information specialist.
The increasing pressures on health care and research budgets are likely to be associated with an increase in the use of factorial trials. This study highlighted the inconsistent use of methods in the health economic analysis of factorial trials. Few studies have compared methods for the analysis of factorial trials. One study found that the different methods led to different conclusions [9] , whilst the other found that choice of method did affect the conclusions of the study. However, the degree to which the intervention was considered cost-effective varied with the different approach i.e. the probability of the intervention being cost-effective differed with the various approaches [11] .
Further research is still required in order to evaluate the impact of alternative methods on policy recommendations and establish good practice guidelines on the design and economic analysis of factorial trials. Until a consensus is reached with respect to the economic analysis of factorial trials, it is suggested that researchers should test for interactions in economic outcomes before deciding on the primary analysis and explore alternative approaches in a secondary analysis. This can be achieved by using a regression approach, which can easily be adapted to take the form of a within-the- 
EXPERT COMMENTARY
In an increasingly resource constrained environment, there is growing interest in employing factorial designs, which assess two or more interventions simultaneously using various combinations of the 
FIVE YEAR VIEW
The increasing pressures on health care and research budgets are likely to be associated with an increase in the use of factorial trials and a corresponding increase in economic evaluations conducted along such trials. With the limited guidance available, it is expected that the inconsistent use of methods in the health economic analysis of factorial trials will continue. However, with the publication of additional studies highlighting the issues surrounding the economic analysis of factorial trials and the potential policy implications, there would be an increased awareness amongst resarchers. We expect to see more research comparing alternative analytical approaches and hope that this would lead to an increase in the development of methods and guidance for the economic analysis of factorial trials over the next five years. 
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• There is a growing interest by health economists in employing factorial trials when analysing economic data in trial-based economic evaluations. However, methods for the economic analysis of factorial trials remain unclear and there seems to be limited guidance on which method is the most appropriate and under which circumstances.
• The results from this study showed that two different methods: 'within-the-table' and 'at-themargins' approaches were used for the analysis. However, with the exception of one study, all others did not consider interactions in costs and outcomes or give a detailed explanation of why a particular approach was adopted.
• This review found that although there was consistency in the application of general principles for conducting economic evaluations, there was lack of agreement with respect to methods for the economic analysis of factorial trials.
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